Novartis Partners with Generate in $1B Biotech Deal
Novartis and Generate forge $1B+ deal to innovate protein therapeutics using generative AI technology.
- Latest
- Trending
Novartis and Generate forge $1B+ deal to innovate protein therapeutics using generative AI technology.
Explore hidden market signals influenced by social media insights and financial trends as of September 26, 2024.
Explore top biotech ETFs like XBI, BBH, and IBB, offering potential returns and portfolio diversification in a growing market.
Amgen plans a new site in Hyderabad to boost digital capabilities and advance its medicine pipeline.
Amgen taps into India's talent with new Hyderabad innovation site for advancing biotechnology and AI.
Stocks surged at the opening but saw steep declines by closing. Learn why tech, Disney, and bond yields impacted the ...
AbCellera Biologics Inc. progresses with their TCE platform and strategic partnerships, aiming for CTA submissions in Q2 2025.
Amgen's Q2 profit drops due to higher expenses, but revenue sees a 20% increase, driven by Horizon acquisition.
"Discover 7 breakthrough biotech stocks poised to boost your portfolio in a sector projected to reach $521.6B by 2033. Learn ...
Amazon.com Inc (NASDAQ:) and Sunshine Biopharma Inc (NASDAQ:) were the worst performers, while American Express Company (NYSE:) and Top Wealth ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.